2015 Conference on Retroviruses and Opportunistic Infections
CROI 2015 "brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases."
NS5A/ NS3 Combo Hepatitis C Treatment Delivers Excellent Sustained Virologic Response in Patients Coinfected with HIV
Pre-exposure prophylaxis (PrEP) is a strategy with significant historical precedent in the infectious disease field. Applied to HIV prevention, at-risk individuals would take PrEP to protect against HIV acquisition in case of any planned or unplanned exposure, potentially permitting HIV prophylactic control by the uninfected individual.
Bristol-Myers Squibb today announced that its Phase III clinical trial of a combination product daclatasvir-sofosbuvir showed dramatic cure rates for patients infected with both HIV and Hepatitis C. The results of the trial, known as ALLY-2, were presented at the 2015 Conference on Retroviruses and Opportunistic Infections in Seattle, WA.